Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin® (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer.
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Details
- Category: Eli Lilly and Company
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions.
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
- Details
- Category: Genzyme
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition
- Details
- Category: Boehringer Ingelheim
As part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.
Phase III trial of Novartis drug Afinitor® met primary endpoint
- Details
- Category: Novartis
Novartis announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)[1],[2],[6].
Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value.
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.
More Pharma News ...
- Amgen and UCB Team Up with NASA
- London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia
- Bayer advances research in the area of pulmonary hypertension
- AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration
- Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma